“However beautiful the strategy,
you should occasionally
look at the results.”
Winston Churchill
OUR COMPANY
Stracotek is a Limited Liability Company formed in 2016 with headquarters in Texas, USA. Our company provides high quality products and technical services to the radiopharmaceutical industry. Stracotek is focused in the design of novel target technologies for production of radionuclides. Additionally, Stracotek offers support to Radiopharma facilities from the project to the production stages, focusing on quality and reliability.
Our team has extensive experience in designing high throughput, high reliability, low operational cost and low maintenance liquid targets. We are diligently working to transfer these features to new target technologies for production of radiometals.
Mission
Our mission is to provide expanded access to existing and new radiopharmaceuticals for P.E.T. (Positron Emission Tomography) diagnostic imaging technologies.
Vision
Our vision is to be a leading supplier of systems for production of radiopharmaceuticals for medical diagnostic imaging.
Background
P.E.T. (Positron Emission Tomography) and S.P.E.C.T. (Single Photon Emission Computed Tomography) are sophisticated molecular imaging modalities that exploit the electromagnetic emissions of radioactive tracer drugs called radiopharmaceuticals. The radioactive elements used to compound or synthesize radiopharmaceuticals are called radionuclides. Typically, radionuclides are artificially generated either in nuclear reactors or particle accelerators, as a product of a nuclear reaction. Commonly, radiopharmaceutical manufacturing facilities employ cyclotrons, which accelerate electrically charged particles and use them to induce nuclear reactions by bombarding a particular material. The material container, where the nuclear reaction occurs, is called Target.
The above-mentioned imaging modalities are used in nuclear medicine to detect the presence and spread of tumors, cardiac diseases, neurologic and endocrine disorders, etc. Detection at an early stage provides a better chance for patient recovery and/or increases patients quality of life.